KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 570.8 USD | -2.27% | -3.22% | +7.60% | 11.69% | ||
| 22.95 USD | -7.61% | -10.77% | -24.76% | 11.15% | ||
| 54.56 USD | -1.24% | -0.84% | -13.26% | 8.55% | ||
| 24.17 USD | -0.62% | -3.15% | -11.76% | 8.03% | ||
| 2.965 USD | -0.17% | -4.39% | -48.44% | 6.97% | ||
| 2.855 USD | -3.87% | -4.71% | -15.77% | 4.87% | ||
| 5.285 USD | -6.13% | -4.45% | -48.03% | 4.83% | ||
| 154.7 USD | -1.52% | -5.25% | -0.38% | 4.81% | ||
| 6.47 USD | -6.57% | -20.05% | -27.54% | 4.71% | ||
| 5.21 USD | -1.33% | -6.50% | -62.84% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
